Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

por Saine, M Elle, Carbonari, Dena M, Newcomb, Craig W, Nezamzadeh, Melissa S, Haynes, Kevin, Roy, Jason A, Cardillo, Serena, Hennessy, Sean, Holick, Crystal N, Esposito, Daina B, Gallagher, Arlene M, Bhullar, Harshvinder, Strom, Brian L, Re, Vincent Lo
Publicado 2015

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

por Lo Re, Vincent, Carbonari, Dena M, Saine, M Elle, Newcomb, Craig W, Roy, Jason A, Liu, Qing, Wu, Qufei, Cardillo, Serena, Haynes, Kevin, Kimmel, Stephen E, Reese, Peter P, Margolis, David J, Apter, Andrea J, Reddy, K Rajender, Hennessy, Sean, Bhullar, Harshvinder, Gallagher, Arlene M, Esposito, Daina B, Strom, Brian L
Publicado 2017